|
|
 Previous Article | Table of Contents | Next Article 
RAPID COMMUNICATION
Improved Sensitivity of BCR-ABL Detection: A Triple-Probe Three-Color Fluorescence In Situ Hybridization System
P.B. Sinclair,
A.R. Green,
C. Grace, and
E.P. Nacheva
From the Department of Haematology, Addenbrooke's Hospital, Cambridge, UK; the Department of Haematology, University of Cambridge, MCR Center, Cambridge, UK; and Digital Scientific, Cambridge, UK.
Chronic myeloid leukemia is a clonal stem cell disorder associated with the Philadelphia (Ph) translocation [t(9; 22) (q34; q11)]. As a result of the Ph translocation, parts of the ABL and BCR genes become fused. Cytogenetic quantification of Ph+ metaphases can be used to monitor patient response to treatment but is of limited sensitivity and applies only to cycling cells. Fluorescence in situ hybridization (FISH) with probes from the BCR and ABL regions can also identify the Ph translocation in interphase cells. Established systems for the detection of fusion genes by FISH rely on colocalization of two different probes but are associated with a high rate of false-positive results. We have introduced a third probe labeled with a different fluorochrome to create a triple-probe/three-color system that permits identification of both the Ph chromosome and the derivative 9 chromosome in Ph+ cells. This system was used to determine the frequency of interphase cells carrying the BCR-ABL fusion gene in bone marrow and peripheral blood granulocytes from patients showing variable cytogenetic responses to interferon. Our data show that the triple-probe/three-color approach allows highly sensitive detection of residual disease. Moreover, this method is readily applicable to the analysis of other chromosome translocations.
Blood, Vol. 90 No. 4 (August 15), 1997:
pp. 1395-1402
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Kantarjian, C. Schiffer, D. Jones, and J. Cortes
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
Blood,
February 15, 2008;
111(4):
1774 - 1780.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B. Sinclair, A. Sorour, M. Martineau, C. J. Harrison, W. A. Mitchell, E. O'Neill, and L. Foroni
A Fluorescence in Situ Hybridization Map of 6q Deletions in Acute Lymphocytic Leukemia: Identification and Analysis of a Candidate Tumor Suppressor Gene
Cancer Res.,
June 15, 2004;
64(12):
4089 - 4098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. P. Huntly, A. Bench, and A. R. Green
Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia
Blood,
August 15, 2003;
102(4):
1160 - 1168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F. Sanz, S. Saavedra, D. Planelles, L. Senent, J. Cervera, E. Barragan, C. Jimenez, L. Larrea, G. Martin, J. Martinez, et al.
Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies
Blood,
October 15, 2001;
98(8):
2332 - 2338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. P. Huntly, A. G. Reid, A. J. Bench, L. J. Campbell, N. Telford, P. Shepherd, J. Szer, H. M. Prince, P. Turner, C. Grace, et al.
Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia
Blood,
September 15, 2001;
98(6):
1732 - 1738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jackson, P. Carrara, V. Duke, P. Sinclair, M. Papaioannou, C. J. Harrison, and L. Foroni
Deletion of 6q16-q21 in Human Lymphoid Malignancies: A Mapping and Deletion Analysis
Cancer Res.,
June 1, 2000;
60(11):
2775 - 2779.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B. Sinclair, E. P. Nacheva, M. Leversha, N. Telford, J. Chang, A. Reid, A. Bench, K. Champion, B. Huntly, and A. R. Green
Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia
Blood,
February 1, 2000;
95(3):
738 - 743.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grand, S. Kulkarni, A. Chase, J. M. Goldman, M. Gordon, and N. C. P. Cross
Frequent Deletion of hSNF5/INI1, a Component of the SWI/SNF Complex, in Chronic Myeloid Leukemia
Cancer Res.,
August 1, 1999;
59(16):
3870 - 3874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Buno, W. A. Wyatt, A. R. Zinsmeister, J. Dietz-Band, R. T. Silver, and G. W. Dewald
A Special Fluorescent In Situ Hybridization Technique to Study Peripheral Blood and Assess the Effectiveness of Interferon Therapy in Chronic Myeloid Leukemia
Blood,
October 1, 1998;
92(7):
2315 - 2321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Dewald, W. A. Wyatt, A. L. Juneau, R. O. Carlson, A. R. Zinsmeister, S. M. Jalal, J. L. Spurbeck, and R. T. Silver
Highly Sensitive Fluorescence In Situ Hybridization Method to Detect Double BCR/ABL Fusion and Monitor Response to Therapy in Chronic Myeloid Leukemia
Blood,
May 1, 1998;
91(9):
3357 - 3365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
